Insider Transactions in Q4 2022 at Monopar Therapeutics (MNPR)
Insider Transaction List (Q4 2022)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 31
2022
|
Chandler Robinson Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,814
-6.24%
|
$9,628
$2.37 P/Share
|
Dec 31
2022
|
Chandler Robinson Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,912
+15.28%
|
-
|
Dec 31
2022
|
Kim R Tsuchimoto Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,067
-10.42%
|
$4,134
$2.37 P/Share
|
Dec 31
2022
|
Kim R Tsuchimoto Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,067
+20.34%
|
-
|
Dec 31
2022
|
Andrew Cittadine Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,406
-4.97%
|
$2,812
$2.37 P/Share
|
Dec 31
2022
|
Andrew Cittadine Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,062
+12.55%
|
-
|
Dec 31
2022
|
Christopher M Starr Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,859
+15.38%
|
-
|
Dec 31
2022
|
Arthur J Klausner Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,859
+12.12%
|
-
|
Dec 31
2022
|
Michael J Brown Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,859
+1.25%
|
-
|
Dec 31
2022
|
Raymond Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,859
+14.59%
|
-
|
Nov 15
2022
|
Andrew Cittadine Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+29.21%
|
$30,000
$3.15 P/Share
|
Nov 14
2022
|
Andrew Cittadine Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
6,053
+29.83%
|
$18,159
$3.0 P/Share
|